FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2120116963> ?p ?o ?g. }

• W2120116963 endingPage "1219" @default.
• W2120116963 startingPage "1214" @default.
• W2120116963 abstract "Objective. To evaluate the effects of the anti-TNF-α monoclonal antibody golimumab, administered by s.c. injection or i.v. infusion, on markers of inflammation in patients with RA. Methods. In this phase 1, open-label study, patients with active RA were randomized to receive s.c. golimumab 100 mg at baseline and every 4 weeks through week 20 (n = 33; group 1) or i.v. golimumab 2 mg/kg at baseline and week 12 (n = 16; group 2). Serum levels of CRP, IL-6, serum amyloid A (SAA), TNF receptor II (TNFRII), MMP-3, hyaluronic acid, haptoglobin, ferritin and haemoglobin and serum/urine hepcidin were measured at various time points. Associations between the biomarkers were assessed with Spearman’s correlations. Results. In both groups 1 and 2, decreases in mean serum levels of CRP, IL-6, SAA, TNFRII, MMP-3, haptoglobin, ferritin and hepcidin, and mean urine levels of hepcidin occurred within 1 week and were sustained through week 8. Decreases in concentrations of serum CRP, IL-6, SAA, MMP-3, hepcidin, ferritin and haptoglobin and urine hepcidin were maintained through week 24 in group 1, but began to reverse after week 8 in group 2. Among all patients, decreases in serum hepcidin correlated significantly with decreases in serum CRP and ferritin. Conclusion. Decreases in serum and urine concentrations of markers of inflammation occurred as early as 24 h after treatment with golimumab, and most of these improvements were sustained through week 24 in group 1." @default.
• W2120116963 created "2016-06-24" @default.
• W2120116963 creator A5000613441 @default.
• W2120116963 creator A5001754270 @default.
• W2120116963 creator A5023944330 @default.
• W2120116963 creator A5026361821 @default.
• W2120116963 creator A5030540014 @default.
• W2120116963 creator A5049709428 @default.
• W2120116963 creator A5050721137 @default.
• W2120116963 creator A5051248102 @default.
• W2120116963 creator A5052078671 @default.
• W2120116963 creator A5056014905 @default.
• W2120116963 creator A5090742492 @default.
• W2120116963 date "2013-02-14" @default.
• W2120116963 modified "2023-10-10" @default.
• W2120116963 title "Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open-label trial" @default.
• W2120116963 cites W1966756501 @default.
• W2120116963 cites W1988975600 @default.
• W2120116963 cites W2016528960 @default.
• W2120116963 cites W2019251546 @default.
• W2120116963 cites W2022477691 @default.
• W2120116963 cites W2043254960 @default.
• W2120116963 cites W2043597254 @default.
• W2120116963 cites W2045599643 @default.
• W2120116963 cites W2080322132 @default.
• W2120116963 cites W2090165219 @default.
• W2120116963 cites W2100586280 @default.
• W2120116963 cites W2101840353 @default.
• W2120116963 cites W2140965629 @default.
• W2120116963 cites W2149849218 @default.
• W2120116963 cites W2152348310 @default.
• W2120116963 cites W2157198188 @default.
• W2120116963 cites W2158058290 @default.
• W2120116963 cites W2170375210 @default.
• W2120116963 cites W4249150518 @default.
• W2120116963 cites W4252676322 @default.
• W2120116963 cites W4362054083 @default.
• W2120116963 doi "https://doi.org/10.1093/rheumatology/kes381" @default.
• W2120116963 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23418046" @default.
• W2120116963 hasPublicationYear "2013" @default.
• W2120116963 type Work @default.
• W2120116963 sameAs 2120116963 @default.
• W2120116963 citedByCount "37" @default.
• W2120116963 countsByYear W21201169632013 @default.
• W2120116963 countsByYear W21201169632014 @default.
• W2120116963 countsByYear W21201169632015 @default.
• W2120116963 countsByYear W21201169632016 @default.
• W2120116963 countsByYear W21201169632017 @default.
• W2120116963 countsByYear W21201169632018 @default.
• W2120116963 countsByYear W21201169632019 @default.
• W2120116963 countsByYear W21201169632020 @default.
• W2120116963 countsByYear W21201169632021 @default.
• W2120116963 countsByYear W21201169632022 @default.
• W2120116963 crossrefType "journal-article" @default.
• W2120116963 hasAuthorship W2120116963A5000613441 @default.
• W2120116963 hasAuthorship W2120116963A5001754270 @default.
• W2120116963 hasAuthorship W2120116963A5023944330 @default.
• W2120116963 hasAuthorship W2120116963A5026361821 @default.
• W2120116963 hasAuthorship W2120116963A5030540014 @default.
• W2120116963 hasAuthorship W2120116963A5049709428 @default.
• W2120116963 hasAuthorship W2120116963A5050721137 @default.
• W2120116963 hasAuthorship W2120116963A5051248102 @default.
• W2120116963 hasAuthorship W2120116963A5052078671 @default.
• W2120116963 hasAuthorship W2120116963A5056014905 @default.
• W2120116963 hasAuthorship W2120116963A5090742492 @default.
• W2120116963 hasBestOaLocation W21201169631 @default.
• W2120116963 hasConcept C126322002 @default.
• W2120116963 hasConcept C134018914 @default.
• W2120116963 hasConcept C203014093 @default.
• W2120116963 hasConcept C206396517 @default.
• W2120116963 hasConcept C2776768029 @default.
• W2120116963 hasConcept C2776914184 @default.
• W2120116963 hasConcept C2777226972 @default.
• W2120116963 hasConcept C2777575956 @default.
• W2120116963 hasConcept C2778319317 @default.
• W2120116963 hasConcept C2780026642 @default.
• W2120116963 hasConcept C2781290027 @default.
• W2120116963 hasConcept C55359608 @default.
• W2120116963 hasConcept C57194454 @default.
• W2120116963 hasConcept C71924100 @default.
• W2120116963 hasConcept C90924648 @default.
• W2120116963 hasConceptScore W2120116963C126322002 @default.
• W2120116963 hasConceptScore W2120116963C134018914 @default.
• W2120116963 hasConceptScore W2120116963C203014093 @default.
• W2120116963 hasConceptScore W2120116963C206396517 @default.
• W2120116963 hasConceptScore W2120116963C2776768029 @default.
• W2120116963 hasConceptScore W2120116963C2776914184 @default.
• W2120116963 hasConceptScore W2120116963C2777226972 @default.
• W2120116963 hasConceptScore W2120116963C2777575956 @default.
• W2120116963 hasConceptScore W2120116963C2778319317 @default.
• W2120116963 hasConceptScore W2120116963C2780026642 @default.
• W2120116963 hasConceptScore W2120116963C2781290027 @default.
• W2120116963 hasConceptScore W2120116963C55359608 @default.
• W2120116963 hasConceptScore W2120116963C57194454 @default.
• W2120116963 hasConceptScore W2120116963C71924100 @default.
• W2120116963 hasConceptScore W2120116963C90924648 @default.
• W2120116963 hasIssue "7" @default.
• W2120116963 hasLocation W21201169631 @default.

• next